Thursday, March 29, 2018

Liver Congress™ 2018 - Enanta to present data on EP-027367 for HBV

Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018

Oral presentation to feature preclinical data on novel core inhibitor EP-027367 targeting hepatitis B virus

March 28, 2018 07:30 AM Eastern Daylight Time
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s wholly-owned development programs, including EP-027367, one of Enanta’s novel core inhibitors in preclinical testing for hepatitis B virus (HBV), and EDP-305, an FXR agonist in development for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), have been accepted for presentation at The International Liver Congress™ (ILC) 2018, April 11-15, in Paris, France.

EP-027367, one of several core inhibitors Enanta is evaluating, has been selected for an oral presentation. There will also be three posters on EDP-305, which is currently in a Phase 2 study for NASH and a Phase 2 study for PBC. The U.S. Food and Drug Administration has granted EDP-305 Fast Track designation for the treatment of NASH patients with liver fibrosis and Fast Track designation for the treatment of patients with PBC.

In addition, several abstracts from AbbVie will be presented on their HCV regimens containing glecaprevir/pibrentasvir and marketed under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.). Glecaprevir is Enanta’s second protease inhibitor discovered and commercialized through its protease inhibitor collaboration with AbbVie.

The full ILC 2018 scientific program as well as the abstracts can be found at Further details will be available at the time of these presentations.

Oral Presentation:
Thursday, April 12, 17:45 - 18:00 CET
PS-032 - “Discovery of a novel HBV core inhibitor EP-027367 with potent antiviral activity both in vitro and in a humanized mouse model” (M.Vaine, S.Clugston, J.Kass, X. Gao, H. Cao, W. Li, X. Peng, L.J. Jiang, K. Daniels, Y. Qiu, Y.S. Or, K. Lin)

Poster Presentations
Thursday, April 12, 09:00 - 17:00 CET

THU-469 - “EDP-305 modulates lipoprotein metabolism via distinct chromatin and microRNA regulatory mechanisms” (M. Roqueta-Rivera, M.D. Chau, K. Garlick, Y. Li, G. Wang, Y.S. Or, and L.J. Jiang) 

Friday, April 13, 09:00 - 17:00 CET
FRI-084 - “EDP-305, a highly selective and potent farnesoid X receptor agonist, favorably regulates the expression of key fibrogenic genes in vitro and in vivo” (Y. Li, J.Y. Shang, M.D. Chau, M. Roqueta-Rivera, K. Garlick, P. An, K. Vaid, G. Wang, Y. Popov, Y. S. Or, and L. J. Jiang)
FRI-489 - “Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects” (A. Ahmad, K. Sanderson, D. Dickerson, N. Adda) 

No comments:

Post a Comment